DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+13.83%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$421M
AUM Growth
+$421M
(+25%)
Cap. Flow
+$56.4M
Cap. Flow
% of AUM
13.37%
Top 10 Holdings %
Top 10 Hldgs %
50.23%
Holding
96
New
22
Increased
24
Reduced
22
Closed
7
Top Buys
| 1 |
Nurix Therapeutics
NRIX
|
$9.52M |
| 2 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$7.59M |
| 3 |
Revolution Medicines
RVMD
|
$5.91M |
| 4 |
Protalix BioTherapeutics
PLX
|
$5.37M |
| 5 |
Adicet Bio
ACET
|
$4.02M |
Top Sells
| 1 |
Cassava Sciences
SAVA
|
$3.07M |
| 2 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
$2.9M |
| 3 |
AGTC
Applied Genetic Technologies Corporation
AGTC
|
$2.4M |
| 4 |
Neuronetics
STIM
|
$2.35M |
| 5 |
Neurocrine Biosciences
NBIX
|
$1.8M |
Sector Composition
| 1 | Healthcare | 90.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Sutro Biopharma
STRO
$85.6M
| $1.94M | 0.46% |
85,000
| – | – |
|
52
Apellis Pharmaceuticals
APLS
$3.51B
| $1.93M | 0.46% |
44,926
+1,010
| +2% | +$43.3K |
|
|
BWAY
53
Brainsway
BWAY
$296M
| $1.81M | 0.43% |
+200,000
| New | +$1.81M |
|
54
Athira Pharma
ATHA
$15.5M
| $1.68M | 0.4% |
91,531
+75,000
| +454% | +$1.38M |
|
|
KNTE
55
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $1.65M | 0.39% |
52,915
-15,206
| -22% | -$474K |
|
56
Compugen
CGEN
$133M
| $1.62M | 0.39% |
189,002
+73,800
| +64% | +$634K |
|
57
Arcus Biosciences
RCUS
$1.24B
| $1.62M | 0.38% |
57,600
+8,000
| +16% | +$225K |
|
58
Liquidia Corp
LQDA
$2.52B
| $1.55M | 0.37% |
575,000
| – | – |
|
59
Johnson & Johnson
JNJ
$429B
| $1.55M | 0.37% |
9,400
| – | – |
|
|
KDMN
60
DELISTED
Kadmon Holdings, Inc.
KDMN
| $1.54M | 0.36% |
394,561
-75,800
| -16% | -$295K |
|
|
CBAY
61
DELISTED
Cymabay Therapeutics
CBAY
| $1.53M | 0.36% |
+337,770
| New | +$1.53M |
|
62
KalVista Pharmaceuticals
KALV
$713M
| $1.51M | 0.36% |
+58,600
| New | +$1.51M |
|
|
INFI
63
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $1.48M | 0.35% |
+459,260
| New | +$1.48M |
|
64
Kura Oncology
KURA
$732M
| $1.46M | 0.35% |
51,800
+42,800
| +476% | +$1.21M |
|
|
CFMS
65
DELISTED
Conformis, Inc. Common Stock
CFMS
| $1.29M | 0.31% |
+52,000
| New | +$1.29M |
|
66
Syndax Pharmaceuticals
SNDX
$1.39B
| $1.29M | 0.31% |
57,500
+47,500
| +475% | +$1.06M |
|
|
ALPN
67
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $1.2M | 0.28% |
113,302
+100
| +0.1% | +$1.06K |
|
68
Larimar Therapeutics
LRMR
$337M
| $1.19M | 0.28% |
81,432
+33,004
| +68% | +$482K |
|
|
TPTX
69
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $994K | 0.24% |
+10,509
| New | +$994K |
|
|
OTIC
70
DELISTED
Otonomy, Inc.
OTIC
| $993K | 0.24% |
389,592
| – | – |
|
71
Rigel Pharmaceuticals
RIGL
$710M
| $942K | 0.22% |
+27,550
| New | +$942K |
|
|
GNFT
72
Genfit
GNFT
$198M
| $871K | 0.21% |
188,549
+74,208
| +65% | +$343K |
|
73
Theravance Biopharma
TBPH
$691M
| $840K | 0.2% |
+41,165
| New | +$840K |
|
74
Inogen
INGN
$213M
| $788K | 0.19% |
15,000
| – | – |
|
75
SCYNEXIS
SCYX
$35.2M
| $714K | 0.17% |
89,874
-110,126
| -55% | -$875K |
|